STOCK TITAN

Septerna (SEPN) adds industry veteran Mark A. Wilson as Chief Legal Officer

Filing Impact
(Moderate)
Filing Sentiment
(Neutral)
Form Type
8-K

Rhea-AI Filing Summary

Septerna, Inc. filed a current report describing a leadership expansion. On January 8, 2026, the company issued a press release announcing the appointment of industry veteran Mark A. Wilson as Chief Legal Officer. The press release is included as Exhibit 99.1 and is incorporated by reference for additional details.

The disclosure is made under Regulation FD, meaning the company is sharing information intended to keep all investors equally informed. The information in this item and Exhibit 99.1 is furnished rather than filed, so it is not subject to certain liability provisions of the Exchange Act unless specifically incorporated into another filing.

Positive

  • None.

Negative

  • None.
false 0001984086 0001984086 2026-01-08 2026-01-08
 
 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): January 8, 2026

 

 

Septerna, Inc.

(Exact name of Registrant as Specified in Its Charter)

 

 

 

Delaware   001-42382   84-3891440
(State or Other Jurisdiction
of Incorporation)
  (Commission
File Number)
  (IRS Employer
Identification No.)

 

250 East Grand Avenue  
South San Francisco, California   94080
(Address of Principal Executive Offices)   (Zip Code)

Registrant’s Telephone Number, Including Area Code: 650 338-3533

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

 

Trading
Symbol(s)

 

Name of each exchange
on which registered

Common Stock, par value $0.001 per share   SEPN   The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

 

 
 


Item 7.01 Regulation FD Disclosure.

On January 8, 2026, Septerna, Inc. issued a press release titled “Septerna Expands Leadership with Appointment of Industry Veteran Mark A. Wilson as Chief Legal Officer.” A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

The information in Item 7.01 of this Current Report on Form 8-K, including the accompanying Exhibit 99.1, is intended to be furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, regardless of the general incorporation language of such filing, except as shall be expressly set forth by specific reference in such filing.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

 

99.1    Press Release issued by Septerna, Inc. on January 8, 2026, furnished herewith.
104    Cover Page Interactive Data File (embedded within the Inline XBRL document).


SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

      Septerna, Inc.
Date: January 8, 2026     By:  

/s/ Jeffrey Finer, M.D., Ph.D.

      Jeffrey Finer, M.D., Ph.D.
Chief Executive Officer

FAQ

What leadership change did Septerna (SEPN) report in this Form 8-K?

Septerna reported that it has expanded its leadership team with the appointment of industry veteran Mark A. Wilson as Chief Legal Officer, as described in a press release furnished with the report.

When did Septerna (SEPN) announce the appointment of Mark A. Wilson as Chief Legal Officer?

Septerna announced the appointment of Mark A. Wilson as Chief Legal Officer in a press release issued on January 8, 2026, which is furnished as Exhibit 99.1.

Under which item of Form 8-K did Septerna (SEPN) provide this leadership update?

Septerna provided this leadership update under Item 7.01, Regulation FD Disclosure, indicating it is intended as a fair disclosure of information to investors.

Is the press release about Septerna’s new Chief Legal Officer considered filed or furnished?

The press release in Exhibit 99.1 is designated as furnished, not filed, so it is not automatically subject to Section 18 of the Exchange Act or incorporated into other filings unless specifically referenced.

What exhibits are included with Septerna’s January 8, 2026 Form 8-K?

The Form 8-K includes Exhibit 99.1, a press release dated January 8, 2026, and Exhibit 104, the Cover Page Interactive Data File embedded in the Inline XBRL document.

Who signed Septerna’s January 8, 2026 Form 8-K report?

The report was signed on behalf of Septerna, Inc. by Jeffrey Finer, M.D., Ph.D., who is the company’s Chief Executive Officer.
Septerna, Inc.

NASDAQ:SEPN

SEPN Rankings

SEPN Latest News

SEPN Latest SEC Filings

SEPN Stock Data

1.18B
42.82M
2.94%
100.49%
6.91%
Biotechnology
Pharmaceutical Preparations
Link
United States
SOUTH SAN FRANCISCO